ENDOMETRIN 100 MG — DIN 02334992
PROGESTERONE : 100 MG · FERRING INC · VAGINAL TABLET, EFFERVESCENT · wholesale supply in Canada
Health Canada status: DORMANT
What is ENDOMETRIN?
ENDOMETRIN 100 MG contains PROGESTERONE : 100 MG. It is listed in the Health Canada Drug Product Database under DIN 02334992, held by FERRING INC, supplied as VAGINAL TABLET, EFFERVESCENT for VAGINAL administration. Health Canada currently lists it as dormant, status dated 10-Jul-2025. Nexara Health is a licensed Canadian wholesale distributor (DEL 3-002896-A). This DIN is not currently being marketed in Canada, so it is sourced to order where a compliant route exists rather than held in stock.
What is ENDOMETRIN used for?
Progesterone supplementation in women undergoing in vitro fertilization.
Authorized indication as written in the Health Canada product monograph. For healthcare professionals and licensed purchasers; this is not medical advice.
How much does Progesterone cost around the world?
Progesterone is listed on 13 of the national price registers Nexara ingests. Each country publishes on a different basis, so those figures are not comparable with one another — or with a Canadian wholesale price.
What a market publishes matters more than the number it publishes. Australia publishes a ex-manufacturer; Austria publishes a KVP (Kassenverkaufspreis); Bahrain publishes a retail (max). Comparing an ex-factory ceiling against a pharmacy public price tells you nothing about either, and comparing either against a Canadian landed cost tells you less.
| Market | Price basis published there | Brands | Packs listed | Range |
|---|---|---|---|---|
| United States | acquisition | 4 | 23 | USD███.██ |
| Australia | ex-manufacturer | 8 | 15 | AUD███.██ |
| Czechia | max producer price (ex-factory) | 6 | 13 | CZK███.██ |
| Greece | producer price (ex-factory) | 12 | 12 | EUR███.██ |
| Bahrain | retail (max) | 8 | 10 | BHD███.██ |
| Luxembourg | reimbursement | 9 | 9 | EUR███.██ |
| Saudi Arabia | public | 7 | 8 | SAR███.██ |
| Italy | prezzo al pubblico (classe A) | 7 | 7 | EUR███.██ |
| Hungary | producer price (ex-factory) | 6 | 6 | HUF███.██ |
| Morocco | PPV (public price) | 3 | 6 | MAD███.██ |
| South Africa | single exit price | 6 | 6 | ZAR███.██ |
| United Arab Emirates | public | 4 | 4 | AED███.██ |
| Austria | KVP (Kassenverkaufspreis) | 2 | 2 | EUR███.██ |
121 pack listings across 82 brand entries and 11 price bases, refreshed 08 Sep 2026. Ranges span every Progesterone pack in that market, so a high figure is usually a larger pack rather than the same product.
Canada publishes no comparable public list price. For a delivered Canadian price on a licensed account, verify your licence — it takes about a minute.
Is there a generic Progesterone in Canada, and who makes it?
Every market authorization holder with a Canadian DIN for this molecule, and how many of their listings Health Canada currently shows as marketed.
14 holders have a Canadian DIN containing Progesterone, across 17 DINs, of which 9 are currently marketed. Marketed count is the number that matters: an approval that is not marketed cannot be bought.
| Market authorization holder | DINs | Marketed | Brand names | Position |
|---|---|---|---|---|
| TEVA CANADA LIMITED | 2 | 2 | ACT PROGESTERONE INJECTION, TEVA-PROGESTERONE | Sourceable in Canada |
| PHARMASCIENCE INC | 3 | 1 | PMS-PROGESTERONE, PMS-PROGESTERONE INJ 50MG/ML USP | Sourceable in Canada |
| AURO PHARMA INC | 1 | 1 | AURO-PROGESTERONE | Sourceable in Canada |
| DR. REDDY'S LABORATORIES INC | 1 | 1 | REDDY-PROGESTERONE | Sourceable in Canada |
| EMD SERONO, A DIVISION OF EMD INC., CANADA | 1 | 1 | CRINONE | Sourceable in Canada |
| HIKMA CANADA LIMITED | 1 | 1 | PROGESTERONE INJECTION, USP | Sourceable in Canada |
| ORGANON CANADA INC. | 1 | 1 | PROMETRIUM | Sourceable in Canada |
| SANIS HEALTH INC | 1 | 1 | PROGESTERONE | Sourceable in Canada |
| BESINS HEALTHCARE SA | 1 | 0 | UTROGESTAN | No marketed DIN |
| CYTEX PHARMACEUTICALS INC | 1 | 0 | PROGESTERONE INJ 50MG/ML USP | No marketed DIN |
| EUGIA PHARMA INC. | 1 | 0 | EUGIA-PROGESTERONE | No marketed DIN |
| IBSA INSTITUT BIOCHIMIQUE SA | 1 | 0 | INPROSUB | No marketed DIN |
Health Canada’s Drug Product Database does not flag which listing is the originator and which are subsequent-entry products, so Nexara does not label them here. Interchangeability is determined provincially, not federally — confirm for your province before a formulary switch. Nexara can confirm which of these is actually obtainable, and on what lead time, per order.
How is it supplied and stored?
Pack configuration, storage class and the handling constraints that drive cold-chain planning. One DIN can cover more than one pack size, and the pack — not the DIN — is what gets priced, shipped and invoiced.
| Strength on the label | 100 MG |
|---|---|
| Dosage form | VAGINAL TABLET, EFFERVESCENT |
| Route | VAGINAL |
| Pack configuration (monograph) | 100 mg effervescent vaginal tablets packed individually in a sealed foil pouch, supplied with polyethylene vaginal applicators. |
| Storage | Store at 20-25°C; excursions permitted to 15-30°C. |
Before an order line is unambiguous Nexara needs the strength, the pack size and the presentation.
Substance and classification
| Active substance | Progesterone |
|---|---|
| ATC code | G03DA04 |
| AHFS class | 84:80.00 |
| Biosimilar biologic | No |
Health Canada record and identifiers
The regulatory facts straight from the Drug Product Database, plus every identifier form Nexara accepts on a purchase order. A DIN written without its leading zeros is the commonest reason an order line fails to match.
| DIN (8-digit, as used in ordering) | 02334992 |
|---|---|
| DIN (unpadded, as printed on some documents) | 2334992 |
| Brand name | ENDOMETRIN |
| Generic / active ingredient | PROGESTERONE : 100 MG |
| Market authorization holder | FERRING INC |
| Health Canada schedule | Prescription |
| ATC code | G03DA04 |
| ATC anatomical main group | G — Genito-urinary system and sex hormones |
| ATC therapeutic subgroup | G03DA |
| Current status | DORMANT |
| Status date | 10-Jul-2025 |
| Original market date | 2010-02-01 00:00:00 |
| Status source | Live Health Canada DPD sync |
Verify on the primary sources
How is it administered?
100 mg vaginally 2 or 3 times daily starting the day after oocyte retrieval for up to 10 weeks. Use applicator provided.
Included because it drives pack selection and wastage. Consult the monograph.
Contraindications
Allergy to progesterone; missed abortion; ectopic pregnancy; severe hepatic dysfunction; breast/genital cancer; active/history of thromboembolism; porphyria; undiagnosed vaginal bleeding.
Warnings and precautions
Risk of arterial/venous thromboembolism, myocardial infarction, and vision impairments. Monitor patients with depression, diabetes (glucose tolerance), or conditions affected by fluid retention.
Is Progesterone in shortage in Canada?
A Canadian shortage report is on file for a product containing this molecule: Active — reported by SANIS HEALTH INC, last seen 09 Sep 2026. A shortage on one presentation does not always affect every DIN of the molecule — the alternatives below list what else is marketed in Canada. Nexara can confirm current availability and identify substitutions or import options where permitted.
What can be used instead?
Alternatives on every axis a buyer actually considers — the same molecule in another presentation, the same class, an adjacent class, or a fixed-dose combination. Every row is led by the marketed DIN count, because that is what can be bought this week.
1 · Same molecule, other Canadian presentations
9 of 17 Canadian DINs for this molecule are currently marketed. Marketed products are listed first.
| Product | Strength | Form | Holder | Health Canada status | DIN |
|---|---|---|---|---|---|
| ACT PROGESTERONE INJECTION | 50 MG | SOLUTION | TEVA CANADA LIMITED | MARKETED | 02446820 |
| AURO-PROGESTERONE | 100 MG | CAPSULE | AURO PHARMA INC | MARKETED | 02493578 |
| CRINONE | 8 % | GEL | EMD SERONO, A DIVISION OF EMD INC., CANADA | MARKETED | 02241013 |
| PMS-PROGESTERONE | 100 MG | CAPSULE | PHARMASCIENCE INC | MARKETED | 02476576 |
| PROGESTERONE | 100 MG | CAPSULE | SANIS HEALTH INC | MARKETED | 02516187 |
| PROGESTERONE INJECTION, USP | 50 MG | SOLUTION | HIKMA CANADA LIMITED | MARKETED | 02531828 |
| PROMETRIUM | 100 MG | CAPSULE | ORGANON CANADA INC. | MARKETED | 02166704 |
| REDDY-PROGESTERONE | 100 MG | CAPSULE | DR. REDDY'S LABORATORIES INC | MARKETED | 02463113 |
| TEVA-PROGESTERONE | 100 MG | CAPSULE | TEVA CANADA LIMITED | MARKETED | 02439913 |
| EUGIA-PROGESTERONE | 100 MG | CAPSULE | EUGIA PHARMA INC. | APPROVED | 02546493 |
2 · Same class — other molecules in ATC G03DA
| Molecule | Canadian brands | DINs | Marketed | Sourceable |
|---|---|---|---|---|
| Progesterone | ACT PROGESTERONE INJECTION · AURO-PROGESTERONE · CRINONE · ENDOMETRIN · +12 more | 17 | 9 | Yes |
| Medroxyprogesterone | AA-MEDROXY · DOM-MEDROXYPROGESTERONE · GEN-MEDROXY TABLET 10MG · GEN-MEDROXY TABLET 2.5MG · +16 more | 38 | 7 | Yes |
A molecule with zero marketed DINs cannot be sourced domestically, however many approvals it holds — if one of these sits on a formulary or in an older protocol, that is the line to check.
3 · Adjacent classes in ATC G03D
| ATC subgroup | Molecules | DINs | Marketed |
|---|---|---|---|
| G03DB | Dienogest · Medrogestone | 7 | 5 |
| G03DC | Norethisterone | 1 | 1 |
Not clinical advice. These tables describe what can be supplied in Canada, not what should be prescribed. Substitution within or across classes is a prescriber and pharmacist decision, and interchangeability is determined provincially.
What else is ENDOMETRIN called?
The same molecule, Progesterone, is registered under other names elsewhere. Buyers and prescribers searching from outside Canada — or working from a foreign prescription or tender document — often know it by one of these:
| Name | Script | Registered in |
|---|---|---|
| Utrogestan | Latin | Australia, Czechia, Morocco, Saudi Arabia, South Africa |
| AMELGEN | Latin | Czechia |
| Oripro | Latin | Australia |
| PROGESTERON BESINS | Latin | Czechia |
| PROLUTEX | Latin | Bahrain, Czechia, Saudi Arabia |
| Crinone | Latin | Bahrain, Saudi Arabia |
| CYCLOGEST | Latin | Bahrain |
| GYNPRODYL | Latin | Czechia |
| PROGESTA | Latin | Bahrain |
| PROGESTERONE-APX | Latin | Australia |
| Prometrium | Latin | Australia |
| AGOLUTIN | Latin | Czechia |
| BIOGEST | Latin | Bahrain |
| Endometrin® | Latin | United Arab Emirates |
| GESTOPHIL | Latin | Bahrain |
Names are taken from national medicine registers and published price lists. A product registered abroad is not authorized for sale in Canada unless it holds its own DIN; import is possible only through the routes Health Canada permits.
How can I get it?
This DIN is dormant — it holds a Health Canada authorization but is not currently being marketed in Canada, so it cannot simply be ordered from Canadian stock. Where a patient need exists, supply may be possible through exceptional importation or the Special Access Programme, subject to Health Canada's requirements and the prescriber's application. Nexara can advise on the route and on marketed alternatives.
Ordering questions
Who can buy this from Nexara?
Licensed entities only. Nexara holds Health Canada establishment licence DEL 3-002896-A and ships only to a licensed address. Patients and unlicensed buyers are routed to a partner pharmacy.
Is there a minimum order?
Yes, set per product line and per pack multiple rather than on the order total, so you are never asked to buy a part-pack. The minimum for this line is confirmed with your quote.
What is the lead time?
Confirmed per order at quotation, and it depends on current stock position and whether the product is in shortage.
Why is there no price on this page?
Nexara quotes a delivered Canadian price per order, against a verified licence. Foreign list prices are published on incompatible bases and are not a guide to what any buyer can obtain here, so this page shows which markets list the molecule and on what basis, and nothing more.
Can Nexara supply this for a clinical trial?
Yes — comparator and background-therapy supply, including sourcing from other markets where a Canadian pack will not satisfy the protocol. Clinical trial supply.